Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381693 · ClinicalTrials.gov registry record · Phase 2
Azacitidine in Treating Patients With Myelofibrosis
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00381693: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00381693 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00381693, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well azacitidine works in treating patients with myelofibrosis.
Interventions
- DRUG azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381693
The ClinicalTrials.gov registry entry for NCT00381693 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which azacitidine is the first listed.
NCT00381693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381693 about?
NCT00381693 is a clinical study titled "Azacitidine in Treating Patients With Myelofibrosis". RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well azacitidine works in treating patients with myelofibrosis.
What is the current status of trial NCT00381693?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00381693?
The interventions under investigation include: azacitidine (DRUG).
Who is sponsoring clinical trial NCT00381693?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.